ATE409041T1 - Weibliche verhütungmethode und pharmazeutische zubereitungen die für eine solche methode geeignet sind - Google Patents

Weibliche verhütungmethode und pharmazeutische zubereitungen die für eine solche methode geeignet sind

Info

Publication number
ATE409041T1
ATE409041T1 AT03075905T AT03075905T ATE409041T1 AT E409041 T1 ATE409041 T1 AT E409041T1 AT 03075905 T AT03075905 T AT 03075905T AT 03075905 T AT03075905 T AT 03075905T AT E409041 T1 ATE409041 T1 AT E409041T1
Authority
AT
Austria
Prior art keywords
estradiol
beta
estrogen
amount equivalent
progestogen
Prior art date
Application number
AT03075905T
Other languages
English (en)
Inventor
Bennink Herman Jan Tijmen Coelingh
Monique Visser
Original Assignee
Pantarhei Bioscience Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32798964&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE409041(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pantarhei Bioscience Bv filed Critical Pantarhei Bioscience Bv
Application granted granted Critical
Publication of ATE409041T1 publication Critical patent/ATE409041T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Packaging Of Special Articles (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03075905T 2003-03-28 2003-03-28 Weibliche verhütungmethode und pharmazeutische zubereitungen die für eine solche methode geeignet sind ATE409041T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03075905A EP1462107B1 (de) 2003-03-28 2003-03-28 Weibliche Verhütungmethode und pharmazeutische Zubereitungen die für eine solche Methode geeignet sind

Publications (1)

Publication Number Publication Date
ATE409041T1 true ATE409041T1 (de) 2008-10-15

Family

ID=32798964

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03075905T ATE409041T1 (de) 2003-03-28 2003-03-28 Weibliche verhütungmethode und pharmazeutische zubereitungen die für eine solche methode geeignet sind

Country Status (7)

Country Link
EP (1) EP1462107B1 (de)
AT (1) ATE409041T1 (de)
DE (1) DE60323725D1 (de)
DK (1) DK1462107T3 (de)
ES (1) ES2314156T3 (de)
PT (1) PT1462107E (de)
SI (1) SI1462107T1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4344462C2 (de) 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
CN101198335A (zh) * 2004-09-27 2008-06-11 潘塔希生物科学股份有限公司 雌性避孕的方法以及该用途的药盒
TW200727920A (en) * 2005-06-21 2007-08-01 Organon Nv New regimens for oral monophasic contraceptives
DE102005034498A1 (de) * 2005-07-20 2007-01-25 Grünenthal GmbH Orale Kontrazeption mit Trimegeston

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4383993A (en) * 1980-05-30 1983-05-17 University Of Kentucky Research Foundation Nasal dosage forms containing natural female sex hormones
SE9403389D0 (sv) * 1994-10-06 1994-10-06 Astra Ab Pharmaceutical composition containing derivattves of sex hormones
DE19739916C2 (de) * 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
US6265393B1 (en) * 1998-08-07 2001-07-24 Heinrichs William Leroy Prevention of endometriosis signs or symptons
CA2446849A1 (en) * 2001-05-16 2002-11-21 Endeavor Pharmaceuticals Treatment of conditions relating to hormone deficiencies by administration of progestins
US20040198707A1 (en) * 2001-05-23 2004-10-07 Agatha Antonia Magdalena Van Beek Means and method for hormonal contraception
TR200400183T4 (tr) * 2001-05-23 2004-02-23 Pantarhei Bioscience B.V. Hormonal kontrasepsiyon için vasıta ve metot
WO2003041719A1 (en) * 2001-11-15 2003-05-22 Pantarhei Bioscience B.V. Method of contraception in mammalian females and pharmaceutical kit for use in such method

Also Published As

Publication number Publication date
PT1462107E (pt) 2009-01-02
EP1462107B1 (de) 2008-09-24
SI1462107T1 (sl) 2009-02-28
EP1462107A1 (de) 2004-09-29
DE60323725D1 (de) 2008-11-06
DK1462107T3 (da) 2008-11-03
ES2314156T3 (es) 2009-03-16

Similar Documents

Publication Publication Date Title
Bevelander et al. The effect of the administration of tetracycline on the development of teeth
GB9713140D0 (en) Preparation of pharmaceutical compositions
CO5190672A1 (es) Composicion para la dosificacion oral, de disolucion instantanea
BR0015974A (pt) Uso de levetiracetam, composição farmacêutica, uso de uma composição farmacêutica e métodos para tratar um paciente admintstrado com uma quantidade de pelo menos um composto e uma doença e para potenciar seletivamente o efeito terapêutico de um composto
EP1275381A4 (de) Feste überzogene zubereitungen mit zeitabhängiger freisetzung zur oralen verabreichung
ES2170069T3 (es) 1-alfa-hidroxiprevitamina d para administracion oral.
DK0785775T4 (da) Smelteekstruderede oralt administrerbare opioid-formuleringer
BR0015188A (pt) Composições farmacêuticas
BR0010498A (pt) Composições modernas de medicamentos à base de compostos anticolinergicamente ativos e beta-miméticos
BR9808888A (pt) Formas de dosagem e método de melhorar disfunção erétil masculina
MEP36008A (en) Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
NZ591627A (en) Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
HUP0402142A2 (hu) Kombinációs ösztrogén-gestagen készítmény és alkalmazása
MX173567B (es) Procedimiento para preparar una composicion farmaceutica y composicion farmaceutica para mejorar los sintomas de enfermedad inducida por vih o reducir la transcripcion y proliferacion del vih
BR0114665A (pt) Uso de antiprogestinas para a profilaxia e tratamento de doenças dependentes de hormÈnio
KR970061244A (ko) 치매 치료용 약학 조성물
AR035946A1 (es) Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos
HUP0203721A2 (hu) Új hormonkészítmény és alkalmazása
Katz et al. Burning mouth sensation associated with fusospirochetal infection in edentulous patients
ATE409041T1 (de) Weibliche verhütungmethode und pharmazeutische zubereitungen die für eine solche methode geeignet sind
HRP20020258B1 (en) Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
JPS61176524A (ja) 抗炎症組成物
MX2007009061A (es) Preparacion farmaceutica para la anticoncepcion oral.
HUP9901474A2 (hu) Szekvenciális ösztrogén/progeszteron-antagonista kombináció hormonhelyettesítő terápiához
ATE484516T1 (de) 3.beta.,28-diacetoxy-18-oxo-19,20,21,29,30- pentanorlupan-22-säure solvate, verfahren zu ihrer herstellung und pharmazeutische präparate daraus

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1462107

Country of ref document: EP

REN Ceased due to non-payment of the annual fee